Table 2.
Baseline demographic and clinical characteristics of POMS and ADHD subgroups underwent specific and non specific training
| POMS | |||
| Variable | Specific training (n = 8) | Non specific training (n = 8) | p - value (t, U, or Fisher’s exact test) |
| Sex (F/M) | 5/3 | 4/4 | 1.0 |
| Age, years | 15.8 (2.0) | 15.7 (1.5) | 1.0 |
| Disease Duration, years | 3.5 (3.5) | 3.3 (2.6) | 0.96 |
| Handedness, n. right-handed (%) | 7 (87.5) | 8 (100) | 0.97 |
| Disease modifying therapy, n | |||
| Nothing | 2 | 2 | 0.67 |
| Interferon beta | 6 | 4 | |
| Glatiramer Acetate | 0 | 1 | |
| Natalizumab | 0 | 1 | |
| Annualized Relapse Rate | 0.4 (0.5) | 0.3 (0.5) | 0.72 |
| EDSS, median (min - max) | 2.0 (1.0–3.5) | 3.0 (1.0–3.5) | 0.28 |
| ADHD | |||
| Variable | Specific training (n = 10) | Non specific training (n = 10) | |
| Sex (F/M) | 0/10 | 2/8 | 0.47 |
| Age, years | 11.5 (3.0) | 11.3 (2.0) | 0.58 |
| Handedness, n. right-handed (%) | 9 (90) | 9 (90) | 1.0 |
Abbreviations: POMS pediatric onset multiple sclerosis, EDSS Expanded Disability Status Scale, ADHD Attention Deficit Hyperactivity Disorder